- Aptose Biosciences Inc. has entered into a **US$11.9 million** Amended Facility Agreement with Hanmi Pharmaceutical Co. Ltd. to continue the development of **tuspetinib** for Acute Myeloid Leukemia (AML).  **[882361_0001171843-25-005992_exh_991.htm:0]** 
- This uncommitted loan facility will be administered through multiple advances until **December 31, 2025**, with individual advances not exceeding **US$2,000,000** and an annual interest rate of **6%** on unpaid principal.  **[882361_0001171843-25-005992_exh_991.htm:0]** 
- Aptose also received the **final US$1.4 million advance** from the prior June 2025 Facility Agreement, bringing the total from that agreement to **US$8.5 million**.  **[882361_0001171843-25-005992_exh_991.htm:0]** 
- The company highlighted positive early data from the TUSCANY triplet Phase 1/2 study, where **9 out of 10 patients responded** to tuspetinib triplet therapy, achieving **100% complete remission (CR/CRh)** in the 80mg and 120mg cohorts.  **[882361_0001171843-25-005992_exh_991.htm:0]** 
- The loan agreement is considered a related-party transaction, for which Aptose is relying on a "financial hardship" exemption from certain Canadian securities law requirements.  **[882361_0001171843-25-005992_exh_991.htm:1]**

Aptose Biosciences (APTOF)